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A diagnostic algorithm for pulmonary hypertension due 
to left heart disease in resource-limited settings: can 
busy clinicians adopt a simple, practical approach?
Anastase Dzudie, Andre Pascal Kengne, Kim Lamont, Bonaventure Suiru Dzekem, Leopold Ndemnge 
Aminde, Martin Hongieh Abanda, Friedrich Thienemann, Karen Sliwa 
Abstract
Pulmonary hypertension (PH) has progressively moved from 
an orphan disease to a signiﬁcant global health problem with a 
major disease burden in limited-resource countries, where over 
97% of patients live. The aetiologies of PH differ between high- 
and low-income nations, but PH due to left heart disease is 
credited to be the most frequent contemporary form. Although 
a straightforward diagnosis of PH requires the use of right 
heart catheterisation (RHC), access to equipment for RHC is 
a deterrent. Furthermore, the risk associated with RHC limits 
its uptake to a selection of specialised centres. Moreover, the 
rigour and clinical reasoning for diagnosis in clinical medicine 
is rapidly changing and revealing that PH can complicate a 
diverse range of medical conditions needing other explora-
tions. In this article, we provide for the busy clinician, a simpli-
fied diagnostic algorithm for PH that is relevant for making a 
correct early diagnosis and limiting the impact of PH. 
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Pulmonary hypertension (PH) is an elevation of the pressure in 
the arteries of the lungs, resulting from a variable combination 
of increased pulmonary vascular resistance, pulmonary blood 
ﬂow and pulmonary venous pressure.1 This definition applies 
irrespective of the underlying aetiology of PH, which includes a 
range of medical conditions such as chronic infectious diseases, 
and lung and left heart diseases. Pulmonary arterial hypertension 
(PAH), a specific type of PH, exclusively affects the pulmonary 
arterial circulation, resulting in increased pulmonary vascular 
resistance, and ultimately in right heart failure (HF) and reduced 
life expectancy.
Over the last century, significant progress in the diagnosis and 
management of PH has moved this condition from an orphan 
disease to a multidisciplinary and now acknowledged major 
global health problem. In 2010, it was estimated that PH affects 
more than 25 million individuals worldwide.2,3 The ultimate 
diagnosis is still based on right heart catheterisation (RHC). 
Aetiologies of PH differ between high- and low-income nations, 
but left heart disease (LHD) has progressively been credited to be 
the most common cause of PH in contemporary clinical settings.4,5
Despite these improvements in understanding PH aetiologies, 
the condition is still diagnosed at an advanced stage in a 
significant proportion of patients, due to poor medical awareness 
and the paucity of symptoms in the early stages of the disease.6 
This has negative impacts on subsequent quality of life and 
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survival.7 The American College of Cardiology/American Heart 
Association8 and the European Society of Cardiology/European 
Respiratory Society7 guidelines have each provided a regularly 
updated diagnostic algorithm, based on prevalent aetiologies 
of PH as well as availability of several diagnostic tests, and 
especially, RHC in high-income countries.
This algorithm may not apply or may be difficult to implement 
in low-income countries where human and financial resources 
more than just science often influence the diagnostic approach. 
In sub-Saharan Africa (SSA), given the additional high and 
increasing prevalence of chronic and endemic risk factors of PH, 
which are almost specific to the region, such as chronic infectious 
diseases (HIV, tuberculosis and schistosomiasis), hypertensive 
heart disease, peripartum cardiomyopathies and rheumatic 
heart disease,9 a clear diagnostic approach to PH due to LHD 
(PHLHD) is of particular importance. Furthermore, the high 
cost, low availability and scarcity of expertise for RHC limit its 
utility in this part of the world and justify the interest in a more 
pragmatic algorithm. 
Based on the experience and evidence from the Pan-African 
Pulmonary Hypertension Cohort (PAPUCO) study, we 
previously developed an algorithm,10 and herein suggest a four-
step diagnostic approach for PHLHD in low-resources settings. 
These steps include (1) clinical evaluation to detect predisposing 
conditions for PHLHD, (2) assessment with chest X-ray (CXR) 
and electrocardiogram (ECG) to uncover the presence of 
PHLHD, (3) conﬁrmation of the presence of PHLHD using 
Doppler echocardiography (echo), and (4) exploration of 
differential aetiologies of PHLHD and classiﬁcation of the type 
of PH.
Step 1: clinical evaluation and detection of a 
predisposing condition
Data from the PAPUCO study11 showed that PH should be 
suspected in any African patient with otherwise unexplained 
shortness of breath, fatigue, palpitations, cough, dizziness and/
or signs of right ventricular dysfunction and right heart failure. 
Two-thirds of patients are likely to present in World Health 
Organisation functional class (WHO FC) III or IV and one-third 
may not walk further than 300 metres on a six-minute walk test. 
Clinical examination may reveal a systolic murmur (57%) or a 
loud P2 (41%). These clinical observations are largely similar for 
men and women. 
In the presence of these symptoms, clinicians should actively 
inquire about predisposing conditions, which in the SSA context, 
include hypertension (42%), previous or concurrent tuberculosis 
(22 and 5%, respectively), indoor cooking/heating without 
a chimney (32%) and HIV infection (22% overall). In the 
PAPUCO study, there were no significant differences in the 
risk-factor profiles of men and women besides exposure to 
indoor cooking/heating without a chimney (more women), 
history of smoking (more men) and alcohol abuse (more men). 
Also, although being a traditional risk factor for PH, the 
endemicity of schistosomiasis was only related to one case. In 
some predisposing groups, such as sickle cell disease, PH signs 
and symptoms may often be subtle and may not be apparent for 
months as they are generally non-specific. 
When the clinical evaluation is not suggestive of PH, the 
clinician should search for other causes of symptoms (e.g. 
tuberculosis, chronic pulmonary disease, LHD, malignancy). On 
the other hand, as shown in Fig. 1, when step 1 is suggestive of 
PH, the patient should systematically undergo step 2, non-invasive 
investigations, which should include a CXR and ECG. 
Step 2: the role of chest X-ray and electrocardiogram
Chest X-ray
In SSA where pulmonary tuberculosis and HIV-associated 
chronic lung diseases are common (e.g. recurrent pneumonia, 
pneumocystis pneumonia), CXR allows moderate to severe 
lung diseases to be reasonably excluded but also, abnormalities 
on CXR are frequent in PHLHD and after completion of TB 
treatment. In the PAPUCO registry, 59% of patients presented 
with cardiomegaly and 22% had prominent pulmonary arteries 
(Fig. 2A). 
Other findings supportive of underlying cardiac disease 
include left atrial enlargement, mild to moderate pleural effusion 
and cephalisation. In other circumstances, the presence of 
central pulmonary arterial dilatation, which contrasts with 
‘pruning’ (loss) of the peripheral blood vessels, is very suggestive 
of PH. Right atrial and right ventricular (RV) enlargement may 
be seen in more advanced cases. 
Electrocardiogram
The diagnostic utility of  ECG in patients with PH was 
investigated in a sub-study of the PAPUCO registry.11 Our 
findings demonstrated that a normal ECG is very rare among 
patients with PH. Sinus tachycardia and left ventricular strain 
pattern were observed in around one-fifth of cases (Fig. 2B), 
but PH-specific abnormalities such as p-pulmonale (14%) 
and evidence of right ventricular hypertrophy (19%) were 
documented in less than one-quarter of cases. 
The sensitivity of ECG criteria for right heart strain ranged 
between 6.2 and 47.7%, while specificity ranged between 79.3 
and 100%. Negative predictive value ranged between 81.5 and 
88.9%, and positive predictive value between 25 and 100%. 
Positive predictive value was lowest (25%) for right bundle 
branch block and QRS right-axis deviation (≥ 100°) and highest 
(100%) for QRS axis ≥ +100°, combined with R/S ratio ≥ 1 or R 
in V1 > 7 mm. 
In short, signs involving PH on ECG were highly indicative of 
disease, but a normal ECG would not exclude disease. Because 
ECG patterns focusing on the R and S amplitude in V1 and 
right-axis deviation had good specificity and negative predictive 
value, their presence should trigger further investigation with 
Doppler echo (Fig. 1). 
Step 3: the key role of Doppler echocardiography
A transthoracic Doppler echo examination is the next and most 
appropriate course of study. Doppler echo provides several 
variables that correlate with right heart haemodynamics, including 
an estimate of right ventricular systolic pressure (RVSP), and can 
simultaneously uncover functional and morphological cardiac 
sequelae of PH, and assist in the identiﬁcation of possible 
cardiac causes of PH.
The Doppler echo estimation of RVSP (Fig. 3A) is based on 
the peak velocity of the jet of tricuspid regurgitation (TR). TR 
velocity can be obtained by either a duplex imaging from the 
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right ventricular inflow view, parasternal short-axis view at the 
basal level, para-apical four-chamber view, apical four-chamber 
view, or even the subcostal view. The TR maximal instantaneous 
gradient (TR MIG) is frequently automatically calculated and 
displayed on the screen (Fig. 3A) when the maximal TR velocity 
is measured. Otherwise it is easily calculated using the simpliﬁed 
Bernoulli equation:12 
TR MIG = 4 (TR velocity)²
Bernoulli’s equation then allows for the estimation of the RVSP,12 
taking into account right atrial pressure (RAP): 
RVSP = TR MIG + RAP. 
RAP is estimated from the inferior vena cava (IVC) calibre and 
respiratory collapsibility (Table 1, Fig. 3B). In the absence of 
pulmonary stenosis and acute right HF, the estimated RVSP is 
assumed to equal the pulmonary artery systolic pressure.
Fig. 2.  Chest X-ray and electrocardiogram in pulmonary 
hypertension in sub-Saharan Africa. (A) Postero-
anterior chest X-ray in a 51-year-old HIV-positive 
patient on antiretroviral therapy and with a past history 
of diabetes and one episode of TB, who presented 
with dyspnoea. CXR showing no signs of chronic lung 
disease, but combined heart enlargement and hilar 
pulmonary artery prominence. (B) ECG of a different 
patient showing sinus tachycardia, right atrial enlarge-
ment, right ventricular hypertrophy and strain, and 
right-axis deviation of the QRS complex. Courtesy of 
the PAPUCO investigators group.
A
B
Step 1: clinical examination
Symptoms, signs and 
medical history suggestive 
of PH
Clinical examination 
supportive of PH
Step 2: chest X-ray  
and ECG
Search for other causes, 
e.g. TB, PCP, COPD, LHD, 
malignancy
Chest X-ray and ECG 
supportive of PH
Step 4: 
CTPA, 
V/Q scan
Step 3: Doppler echo
Group 5
Multifactorial
e.g. endo-
myocardial 
fibrosis, sickle 
cell disease
Group 4
CTEPH
Group 2
PH due to left 
heart disease:
e.g. mitral 
stenosis 
due to RHD, 
hypertensive 
heart failure, 
valvular disease, 
coronary artery 
disease
Group 3
PH due to lung 
disease:
e.g. COPD, 
post-TB 
bronchiectasis, 
interstitial lung 
disease
Step 4: liver-
function test, 
HRCT
Group 1
Pulmonary 
arterial 
hypertension 
(PAH): e.g. 
HIV-PAH, 
schistosomiasis, 
drugs/toxins
Step 4: HIV 
testing, urine 
screen, abdominal 
US, drug screen
Step 4: consider common 
causes of PH in Africa
Doppler echo  
supportive of PH
YES
YES
YES
NO
NO
NO
Probably less 
common
Fig. 1.  Diagnostic algorithm to diagnose pulmonary hyperten-
sion due to left heart disease in low-resource settings, 
as evidenced from the PAPUCO study. PH, pulmo-
nary hypertension; TB, tuberculosis; PCP, pneumo-
cystis pneumonia; COPD, chronic obstructive pulmo-
nary disease; LHD, left heart disease; Doppler echo, 
Doppler echocardiography; US, ultrasound; LFT, liver-
function tests; HRCT, high-resolution computerised 
tomography; CTEPH, chronic thromboembolic pulmo-
nary hypertension; CTPA, CT pulmonary angiography; 
V/Q, ventilation/perfusion lung scan.
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TR Vmax = 3.75 m/s
TR MIG = 56 mmHg
Insp diameter = 2.20 cm
Exp diameter = 1.88 cm
IVC collapsing index = 14.5%
ExpInsp
IVSd = 0.85 cm
LVEDd = 7.63 cm
PWd = 0.85 cm
IVSs = 1.2 cm
LVESd = 5.97 cm
PWs = 1.1 cm
EF = 43%
TAPSE = 0.79 cm
LA area = 26.1 cm
LA
E = 1.16 m/s
DT = 122msec
A = 0.36 m/s
E/A = 3.24
E
A
Fig. 3.  Echocardiographic evaluation in patients with pulmonary hypertension in sub-Saharan Africa. Measurement of pulmonary 
pressure is based on identification of the tricuspid regurgitant (TR) jet and using continuous-wave Doppler to obtain the 
maximum instantaneous right ventricular–right atrial gradient, as indicated by the solid yellow line (A). The yellow dotted line 
indicates measurement of over-gained (shaggy) signals with significant overestimation in the gradient. TR Vmax indicates 
TR maximal velocity, TR MIG, TR maximal instantaneous gradient. (B) Right atrial pressure is estimated from the inferior 
vena cava (IVC) calibre and respiratory collapsibility. ins, inspiration, exp, expiration. (C) shows measurements of the ejec-
tion fraction using the Teicholz formula; IV(D/S) indicates interventricular septum (diastole/systole), LVED(S)d: left ventricular 
end-diastolic (systolic) diameter, PWd(s): posterior wall in diastole (systole). (D) indicates the measurement of the tricuspid 
annular plane systolic excursion (TAPSE) in a patient with right heart failure. (E) A visual assessment of right cardiac cavi-
ties in apical four-chamber view showing dilated heart cavities. (F) indicates a restrictive mitral Doppler pattern in the same 
patient. Modified from thesis ‘Predicting pulmonary hypertension and outcomes in patients with left heart disease’. http://hdl.
handle.net/11427/16533. 
A
C
D
B
D
F
CARDIOVASCULAR JOURNAL OF AFRICA • Advance Online Publication, October 2018AFRICA 5
To avoid errors in the measurement of RVSP, it is mandatory 
to observe some conditions, including accurate measurement of 
the IVC, avoiding measuring over-gained (shaggy) signals (Fig. 
3A). If the heart rhythm is irregular, it is recommended that three 
to five consecutive cycles be measured and the mean of these 
cycles be recorded.
In patients with PH, Doppler echo also contributes to the 
evaluation of the RV systolic function through measurement of 
the tricuspid annular plane systolic excursion movement (TAPSE). 
TAPSE represents the distance of systolic excursion of the RV 
annular plane towards the apex. As shown in Fig. 3D, it is obtained 
using an M-mode cursor passed through the tricuspid lateral 
annulus in the four-chamber view and measuring the amount of 
longitudinal displacement of the annulus at peak systole.
In the PAPUCO registry,11 Doppler echo findings showed that 
left ventricular (LV) function was moderately impaired overall 
(median LV ejection fraction 46%) (Fig. 3C). As expected, 
RVSP was markedly elevated (median value 58 mmHg), with 
concurrent moderate to severe right atrial (58%) and right 
ventricular (55%) hypertrophy a common feature. Only one-third 
of cases (n = 69; 33%) showed no evidence of right atrial or 
ventricular enlargement. Overall, 78 patients (37%) presented 
with a diagnosis of right HF based on TAPSE movement < 15 
mm (Fig. 3D) plus one or more clinical signs of HF. 
The LHD aetiology13 of PH is suggested by (1) presence of 
heart disease as suggested by a dilation in the cavities (Fig. 3E), 
presence of heart valve disease or abnormal contractility, and (2) 
arguments suggestive of an elevation of left ventricular filling 
pressure, such as left atrial dilation (Fig. 3E) or a mitral Doppler 
restrictive pattern (Fig. 3F). In the subgroup of patients with 
PHLHD,13 aetiologies were predominantly hypertensive HF with 
reduced or preserved ejection fraction, dilated and peripartum 
cardiomyopathy and rheumatic valvular heart disease. Left 
atrium size and TAPSE were predictors of RVSP in these 
patients, and RVSP predicted short-term hospitalisations but 
not mortality. 
We therefore recommend that an estimated RVSP greater 
than 35 mmHg in SSA should warrant further evaluation for PH 
in patients with suggestive PH in step 1 and/or 2 (Fig. 1). Finally, 
Doppler echo can clearly help identify possible aetiologies 
of PH, and particularly PHLHD (Table 2), anticipating the 
contribution of other tests.
Step 4: other investigations
A careful selection of other tests can contribute to establishing 
a diagnosis of PH in patients residing in low-income countries 
such as SSA. The utilisation of these other investigations will 
depend on both the results of the above initial tests and the 
clinical context. Given the high burden of HIV/AIDS in the 
region as well as its contribution in the PAPUCO registry 
(22%), it is reasonable to screen all patients with PH for HIV. 
Other tests, such as abdominal ultrasound, liver-function test, 
high-resolution computerised tomography (CT), CT pulmonary 
angiography, ventilation/perfusion lung scan, and electrophoresis 
of haemoglobin will be guided by the clinical context. It is only 
after these steps have been completed and once a deﬁnitive 
diagnosis of PH has been reached and potential underlying 
co-morbidities or causes identified, that classification within an 
appropriate aetiological group must be considered (Fig. 4). 
We acknowledge classification difficulties in SSA and other 
low-income countries, especially in the absence of RHC and 
other imaging studies. It noticeable that in some patients, 
several mechanisms may be involved in the pathogenesis of 
PH in Africa. For example, the interaction between sickle cell 
disease-related haemolysis and HIV, chronic lung disease due to 
tuberculosis, schistosomiasis, and viral hepatitis could yield very 
complex multifactorial and unclear PH.
Table 1. Estimation of right atrial pressure from inferior vena cava 
calibre and respiratory collapsibility. Adapted from Beigel et al.12
Estimated RAP (mmHg) IVC diameter (cm)
IVC collapse with  
inspiration (sniff)
5 < 2.1 > 50%
10 < 2.1 < 50%
15 ≥ 2.1 > 50%
20 ≥ 2.1 < 50%
RAP, right atrial pressure; IVC, inferior vena cava.
Table 2. Possible causes of pulmonary hypertension identified by 
echocardiography with relevance to sub-Saharan Africa13
Predisposing conditions for pulmonary hypertension
•	 Valvular disease [mitral (aortic) stenosis/regurgitation, prosthetic valve 
dysfunction]
•	 Left ventricular systolic dysfunction (including hypertensive heart failure, 
dilated cardiomyopathy, peripartum cardiomyopathy, myocardial infarction)
•	 Left ventricular diastolic function (including ischaemic heart disease, hyper-
tensive heart disease, hypertrophic cardiomyopathy, Fabry’s disease, infiltra-
tive cardiomyopathies)
•	 Other obstructive lesions (coarctation, supravalvular aortic stenosis, sub-
aortic membrane, cor triatriatum)
•	 Congenital disease with shunt [atrial (ventricular) septal defect, coronary 
fistula, patent ductus arteriosus, anomalous pulmonary venous return]
•	 Pulmonary embolus (thrombus in inferior vena cava, right-sided cardiac 
chamber, or pulmonary artery; tricuspid or pulmonic valve vegetation)
•	 Pulmonary vein thrombosis/stenosis
Findings that suggest specific disease entity
•	 Left-sided valve changes (systemic lupus erythematous, anorexigen use)
•	 Intra-pulmonary shunts (hereditary haemorrhagic telangiectasia)
•	 Pericardial effusion (idiopathic pulmonary arterial hypertension, systemic 
lupus erythematous, systemic sclerosis)
Group 3
PH due to lung 
disease and/or 
hypoxia.
e.g. COPD or 
tuberculosis
Group 1
Pulmonary arterial 
hypertension.
e.g. HIV-associated PH
Group 2
PH due to left heart disease.
e.g. mitral stenosis due to 
rheumatic heart disease
Group 5
PH with unclear or 
multifactorial mechanism.
e.g. endomyocardial fibrosis
Group 4
Chronic thromboembolic PH.
e.g. chronic pulmonary 
embolism
Fig. 4.  World Health Organisation classification of pulmonary 
hypertension with relevant examples for sub-Saharan 
Africa.1
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Limitations of the suggested algorithm
It is important to acknowledge that a major limitation of our 
approach lies in the validity of RVSP for diagnosis of PH using 
Doppler echo. There is absolutely no doubt that RHC is the 
standard to accurately diagnose PH and determine its severity as 
well as its impact on right ventricular function. However, RHC 
is an invasive procedure, and it is expensive and not available in 
most low-resource settings where the majority of patients with 
PH are resident, particularly in SSA. 
There is abundant literature on the validity of Doppler 
echo RVSP estimates in patients with left heart disease using 
RHC values as the gold standard. Lanzarini et al.14 reported a 
concordance correlation coefficient of 0.88 between RHC and 
RVSP, with ± 20 mmHg and 95% limits of agreement. In their 
study of Doppler echo evaluation of haemodynamics in patients 
with decompensated systolic HF, Nagueh et al.15 reported 
that Doppler echo identified patients with invasive systolic 
pulmonary artery pressure > 35 mmHg with 94% sensitivity and 
90% specificity. 
In an analysis of data from the ESCAPE trial, McClanahan 
and Guglin16 suggested that the accuracy of Doppler echo RVSP 
estimates in systolic HF might be inaccurate in the presence 
of right ventricular systolic dysfunction. However, at least 
two reasons could have explained this lack of accuracy: first, 
patients included in the ESCAPE trial16 were in acute HF and 
not haemodynamically stable; and second, echocardiography 
in ESCAPE was not protocol driven, and the time differential 
between RHC and RVSP evaluation using Doppler echo was 
widely variable. In view of the above and provided that patients 
are haemodynamically stable and a rigorous Doppler echo 
technique is used by experienced observers, it is acceptable and 
pragmatic to detect PH using Doppler echo estimates of RVSP, 
although we recommend a confirmation with RHC before any 
specific therapeutic action is required. 
Finally, our recommendations are based on a single study. 
Ideally, such a practice algorithm, which is intended to provide 
clinicians with recommendations, should be based on systematic 
review of the available evidence, and an assessment of the benefits 
and harms of care options, with the intention of optimising 
patient care and outcomes. However, expert opinion remains a 
major part of all such practice guidelines,17,18 particularly when 
high-quality evidence is lacking, as is the case in SSA. 
Conclusion
For the busy clinician, it is important to recognise the increasing 
burden of PHLHD in low-resource settings and be able to make 
an early diagnosis. Adopting a four-step diagnostic algorithm 
is recommended and the steps include: (1) a clinical evaluation, 
(2) CXR and ECG assessment, (3) Doppler echo, and (4) 
exploration of differential aetiologies before classiﬁcation of 
the type of PH. This strategy will help manage the majority of 
patients in low-resource settings, especially those with various 
types of PHLHD, for which indications of RHC should be 
restricted to avoid unnecessary risk.
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